MustGrow Announces Record Q3-2025 Results
Saskatoon, Saskatchewan--(Newsfi
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2025-11-25 4:00 PM EST | MustGrow Biologics Corp.
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today the completion of enrollment in its ongoing Phase 1b clinical trial of INTASYL siRNA PH-762. In connection with completing enrollment, Phio continues to treat additional patients in the fifth co
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-25 11:30 AM EST | Phio Pharmaceuticals Corp.
OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization
New York, New York--(Newsfile Corp. - November 25, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO) approved 'daznelimgene lisbac' for the non-proprietary name for the Company's HER2 targeted Listeria monocytogenes-based cancer immunotherapy product candidate OST-HER2
2025-11-25 9:21 AM EST | OS Therapies
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injury Completed a U.S. Food and Drug Administration (FDA) Type C meeting in September; FDA confirmed that multiple regulatory routes are available to support approval of NVG-291 as the first pharmacologic treatment for spinal cord injury Completed a US$1
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-24 7:05 AM EST | NervGen Pharma Corp.
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durable and wide-ranging upper and lower-body improvements compared to placebo Participant-reported outcomes highlight substantial improvements in bladder control and muscle spasticity compared to placebo Statistically significant reduction of hyperactive reticulospinal signaling in upper and lower limbs
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-24 7:00 AM EST | NervGen Pharma Corp.
Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
Toronto, Ontario--(Newsfile Corp. - November 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC") as the sole agent and bookrunner on a commercially re
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-11-24 7:00 AM EST | Theralase Technologies Inc.
Skye Bioscience to Participate in Upcoming Investment Conferences
San Diego, California--(Newsfile Corp. - November 24, 2025) - Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following upcoming investment conferences: Citi Global Healthcare Conference (Miami) 1x1 meetings: Dec. 2 Evercore Annual Healthcare Conference (Coral Gables) Fireside Chat: Dec. 3, 12:55 pm
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-11-24 7:00 AM EST | Skye Bioscience, Inc.
Defence Therapeutics Announces Convertible Debenture Conversion
Montreal, Quebec--(Newsfile Corp. - November 21, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), announces that the holders of the Corporation's 8% convertible debentures issued on November 16, 2024 (the "Debentures") have converted all of the principal amount and the accrued interests thereof into an aggregate number of 2,607,600 common
Biotechnology, Pharmaceuticals, Health
2025-11-21 6:03 PM EST | Defence Therapeutics Inc.
PreveCeutical Provides Clarification of News Release Announcing Update on Plan of Arrangement with BioGene Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its news release of earlier today, the Company wishes to clarify that shareholders of record of November 24, 2025 will be issued new common shares of PreveCeutical and 0.02 of one share of BioGene Therapeutics Inc. About PreveCeutical PreveCeutical is a heal
Biotechnology, Pharmaceuticals, Health
2025-11-20 12:26 PM EST | PreveCeutical Medical Inc.
Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia
Calgary, Alberta--(Newsfile Corp. - November 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option patients suffering from pain, angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, is pleased to announce Dr. William R. Shankle, MS,
Biotechnology, Pharmaceuticals, Health
2025-11-20 9:00 AM EST | Hemostemix Inc.
Former US Congressman Dr. Brad Wenstrup Joins Maxwell Board
Austin, Texas--(Newsfile Corp. - November 20, 2025) - Maxwell Biosciences ("Maxwell"), a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Dr. Brad Wenstrup to its Board of Directors. This appointment adds a key national biodefense expert to Maxwell's board.
Biotechnology, Pharmaceuticals
2025-11-20 9:00 AM EST | Maxwell Biosciences, Inc.
Envoy Medical Secures New U.S. Patent for Innovative Cochlear Implant System Featuring a Removable Earplug Sensor and an Implanted Battery
White Bear Lake, Minnesota--(Newsfile Corp. - November 20, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of U.S. Patent No. 12,465,754, granted by the United States Patent and Trademark Office (USPTO) on November 11, 2025. The patent, titled "Combination Implant System with Removable Earplug Sensor and Implanted Battery," repre
Biotechnology, Healthcare and Hospitals
2025-11-20 8:00 AM EST | Envoy Medical, Inc.
OS Therapies to Spinoff OS Animal Health into Standalone Public Company
Successful preliminary discussion with NYSE representatives and potential investors OS Therapies shareholders to receive direct equity participation in new listing 'Shelter Me: Cancer Pioneers' film featuring canine and human patients treated with OST-HER2 receives Anthem Award in the 'Documentary or Film under Awareness Categories, Health' category Company congratulates Disney (NYSE: DIS) for w
2025-11-20 7:40 AM EST | OS Therapies
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
Ontario and Chicago, Illinois--(Newsfile Corp. - November 20, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted Medexus's notice of intention to make a normal course issuer bid, or NCIB, for its common shares (TSX: MDP). Under the NCIB, Medexus may purchase for cancellation up to 2,983,650 common shares, representing approximately 10% of the public float as defined under TSX rules. As of November 12, 2025, 32
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-20 7:30 AM EST | Medexus Pharmaceuticals Inc.
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its News Releases of September 4, 2025, September 19, 2025, October 10, 2025 and October 20, 2025, the Company announces that it will be completing
Biotechnology, Pharmaceuticals, Health
2025-11-20 7:00 AM EST | PreveCeutical Medical Inc.
NervGen Pharma Announces Closing of US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it has completed its previously announced non-brokered private placement (the "Non-Brokered Unit Offering") to certain institutional investors and other acc
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-19 4:26 PM EST | NervGen Pharma Corp.
Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology
Montreal, Quebec--(Newsfile Corp. - November 19, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), is pleased to announce a major step forward in the fight against cancer that goes beyond the ADCs current limitations. Following successful presentations and meetings at the World ADC Conference in San Diego with ADC companies as well as
Biotechnology, Pharmaceuticals, Health
2025-11-19 3:15 AM EST | Defence Therapeutics Inc.
Resverlogix Appoints Bradley Glass to Board of Directors
Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Company") today announces the appointment of Mr. Bradley Glass, J.D. as a member of the Company's board of directors. Mr. Glass has served as the General Counsel of Hepalink USA, Inc. and its subsidiaries ("Hepalink") for the past four years. In that role, Mr. Glass is responsible for managing all of Hepalink's U.S. legal issues. Prior to joining Hepalink, Mr. Glass wa
Technology, Biotechnology, Healthcare and Hospitals
2025-11-18 5:15 PM EST | Resverlogix Corp.
Hemostemix Closes CDN$280,594 Private Placement
Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida
Biotechnology, Pharmaceuticals, Health
2025-11-18 5:08 PM EST | Hemostemix Inc.
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that it is conducting a non-brokered private placement (the "Non-Brokered Unit Offering") to certain institutional investors and other accredited inves
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-18 4:42 PM EST | NervGen Pharma Corp.